More than 130 different genes can cause retinitis pigmentosa, the most common inherited cause of blindness. The only approved gene therapy, Luxturna, approved in 2017, helps only the two percent of patients with mutations in the RPE65 gene. For everyone else, there was no treatment option until now. In October 2025, the first patient received SPVN20, a gene therapy designed to fundamentally address this gap.
How Retinitis Pigmentosa Steals Sight
Retinitis pigmentosa is the most common inherited retinal disease: approximately 1.5 million people worldwide are affected, roughly one in 4,000 to 5,000 people. The disease typically begins with loss of rod cells in the retina, the photoreceptors responsible for vision in dim light and in peripheral vision. What initially appears as mild night blindness often progresses to tunnel vision. Later, damage spreads to the cone cells that handle central vision and color perception. In severe cases, total blindness results.
What makes the disease so difficult to treat is its genetic diversity. More than 130 different genes can be mutated to cause RP; researchers have identified nearly 3,100 distinct mutations in these genes. Each patient often carries a unique genetic signature.
Why Previous Therapies Help So Few
Luxturna, approved by the FDA in December 2017, was a landmark: the world's first gene therapy for an inherited form of blindness. It delivers a functioning copy of the RPE65 gene into the retina via an AAV vector and has measurably improved vision in patients with this specific mutation. The problem: RPE65 mutations account for roughly two percent of all RP cases. For the other 98 percent of patients with mutations in RHO, USH2A, RPGR and more than 130 other genes, Luxturna has no effect.
A parallel research approach is optogenetics: GenSight Biologics began testing GS030 in the PIONEER Phase 1/2 study starting in 2021, a therapy that reactivates blinded retinal cells with light-sensitive proteins. Early case reports in Nature Medicine showed encouraging signals. One 58-year-old patient who had been blind for 40 years could locate objects on a table and recognize zebra stripes on a street after treatment. A second patient achieved a 57 percent success rate in finding objects 12 months after injection. Critical limitation: GS030 therapy requires special video glasses that convert natural light for the treated cells.
How a Potassium Channel Awakens Dormant Cone Cells
SPVN20 targets a different problem: Cone cells in RP retinas die more slowly than rod cells and remain abundant in many patients even when vision is severely impaired. Their problem is not that the cones themselves are missing, but that they have lost the ability to convert light into electrical signals. They are silent, not dead.
According to company statements, SparingVision delivers a one-time injection into the eye's vitreous that carries an AAV vector carrying the gene for a GIRK channel (a G-protein-coupled potassium channel) into these dormant cone cells. This channel should enable the cells to respond to light again and relay visual signals to the brain. Because the approach does not correct the defective gene itself but rather gives the cone cell a new signaling pathway, the specific genetic cause is irrelevant. Deniz Dalkara, researcher at the Institut de la Vision in Paris and scientific director of SparingVision, developed this concept from the observation that inactive cone cells in advanced RP stages survive but no longer send signals.
In Perspective: The Limits of Single-Gene Therapy
With more than 130 genetic causes of RP, an approach like Luxturna would require 130 separate development programs, each for a rare mutation, each with decades of development time and billions in costs. In practice, availability is already severely limited: In Australia, only 20 people had been treated with Luxturna by August 2025. The therapy costs roughly $850,000 in the United States for both eyes.
SPVN20 would fundamentally change this framework: a single therapy for all patients with surviving but silent cone cells, instead of 130 separate programs. SparingVision also sees additional potential in dry age-related macular degeneration, the world's leading cause of blindness, where a similar mechanism of cone cell degeneration occurs.
First Efficacy Data Expected in 2027
The NYRVANA study is an open-label, multicenter Phase 1/2 dose-escalation trial. The first patient was treated in October 2025 in Belgium, with France and Ireland expanding recruitment. The study primarily evaluates safety and tolerability in the first six months, followed by a five-year follow-up. SparingVision expects first efficacy data in 2026 and 2027.
For SPVN20 to eventually become an approved therapy, several conditions must be met: Safety data from NYRVANA must show no unexpected risks. Efficacy signals must be strong enough to justify a Phase 3 trial. And AAV vector production must be scaled sufficiently, which is regularly a bottleneck in gene therapies. SparingVision plans to apply for US study approval in 2026. If all steps proceed as planned, regulatory approval is likely still five to seven years away. The first step in humans has been taken.